Le Lézard
Classified in: Health
Subject: SVY

DRG Expects the Pancreatic Cancer Market to Grow at an annual rate of 10% over the next 10 years to Reach Almost $4 Billion in 2026



BURLINGTON, Mass., Oct. 6, 2017 /PRNewswire/ -- Decision Resources Group finds that the pancreatic cancer market will grow from $1.3 billion in 2016 to $3.7 billion in 2026. This growth will be fueled by the increased penetration of existing branded chemotherapy agents, and the approval of novel premium-priced targeted agents for the treatment of metastatic disease.

Decision Resources Group Logo. (PRNewsFoto/Decision Resources Group)

Other key findings from the Disease Landscape & Forecast report entitled Pancreatic Cancer:

Comments from Decision Resources Group Analyst Anamika Ghosh, PhD:

Additional Resources:

For more information on purchasing this report, please visit our website.

About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.

Media contact:

Decision Resources Group
Stephanie Cooper
212-414-7570
scooper@dresources.com

SOURCE Decision Resources Group


These press releases may also interest you

23 jun 2018
One Drop, a leader in the development of digital therapeutics solutions for people with diabetes, today announced the launch of Blood Glucose Prediction and Automated Decision Support. Through these new features, the One Drop | Mobile app will...

23 jun 2018
New research finds that people with type 1 diabetes (T1D) who used the Diabeloop DBLG1 therapeutic, closed-loop insulin delivery system in a home setting experienced a greater percentage of time in the target blood glucose range and fewer...

23 jun 2018
When adolescents and adults with type 1 diabetes (T1D) used a new continuous glucose monitoring (CGM) device containing a sensor that can remain implanted in the arm for up to 180 days, the system provided accurate glucose measurement with no major...

23 jun 2018
A dual-hormone, artificial pancreas1 delivering rapid insulin and the drug pramlintide improved glucose control and reduced glucose variability in adults with type 1 diabetes (T1D) compared to an insulin-only, first-generation artificial pancreas,...

23 jun 2018
Adults with type 1 diabetes using the Omnipod hybrid closed-loop system (the Horizontm Automated Glucose Control System) were studied in a supervised outpatient hotel setting with unrestricted meals and moderate-intensity exercise and  experienced...

23 jun 2018
Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE)...




News published on 6 october 2017 at 08:30 and distributed by: